Skip to main content

Table 2 Antimicrobial susceptibility of ESBL-producing Escherichia coli isolates from different areas

From: Epidemiology of CTX-M-type extended-spectrum beta-lactamase (ESBL)-producing nosocomial -Escherichia coli infection in China

Antimicrobial agent Hainan (n = 19) Hebei (n = 21) Chongqing (n = 30) Henan (n = 30) Tianjin (n = 30)
Ampicillin 100 100 100 100 100
Piperacillin 100 100 100 100 93.3
Cefotaxime 94.7 100 100 100 90
Cefepime 68.4 95.2* 93.3 90 83.3
Cefuroxime 100 100 100 100 96.7
Cefoxitin 15.8 23.8 36.7 16.7 20
Ceftazidime 26.3 61.9* 56.7* 63.3* 53.3
Aztreonam 5.3 61.9** 73.3** 76.7** 60**
Imipenem 0 0 3.3 6.7 0
Meropenem 0 0 6.7 0 0
Amoxicillin/Clavulanic acid 84.2 9.5** 43.3** 50* 20**
Ampicillin/Sulbactam 73.7 71.4 80 83.3 76.7
Piperacillin/Tazobactam 5.3 0 23.3 3.3 6.7
Trimethoprim-sulfamethoxazole 78.9 85.7 83.3 83.3 73.3
Ciprofloxacin 68.4 90.5 70 76.7 60
Levofloxacin 47.4 90.5** 70 76.7* 60
Amikacin 5.3 0 16.7 6.7 6.7
Gentamycin 52.6 85.7* 63.3 66.7 76.7
  1. **P < 0.01 and *P < 0.05.